ON
← Back to feed
STAT+: Medicare takes another swing at 340B cuts to hospitals
United States🏛️ Politicsyesterday

STAT+: Medicare takes another swing at 340B cuts to hospitals

Medicare has proposed reducing payments to hospitals for drugs purchased through the 340B drug discount program by over a third starting next year. This comes after Medicare's surveys indicated that some patients were paying more for these drugs than the hospitals did. Under the new proposal, Medicare would reimburse hospitals at the average sales price of the drugs minus 33.4%, significantly lower than the current rate of that price plus 6%. The proposal is part of a broader rule on hospital outpatient payments and has sparked controversy, with nonprofit and academic hospitals criticizing it for potentially harming safety-net providers. These hospitals are the only ones eligible for the 340B program, while for-profit hospitals would see a 7.4% pay increase under the same adjustment.

The Trump administration has unveiled a controversial plan aimed at reducing payments to hospitals for certain medical services, specifically imaging procedures, which could significantly impact healthcare costs for seniors. This move comes as part of broader efforts to reshape federal healthcare spending and align it with cost-saving measures. Under the proposed rule from the Centers for Medicare and Medicaid Services (CMS), hospitals would receive reduced reimbursements for imaging services, potentially leading to lower out-of-pocket expenses for patients covered by Medicare. The initiative reflects a growing push within the administration to scrutinize and adjust payment structures within the U.S. healthcare system.

According to reports, the proposed changes were announced in July 2026, marking a significant shift in how Medicare funds hospital-based diagnostic services. The policy aims to equalize payments between different types of healthcare providers, but critics argue it could lead to unintended consequences, particularly for vulnerable patient populations. The decision was framed as a necessary step toward fiscal responsibility, though it has sparked intense debate among healthcare professionals, advocacy groups, and policymakers.

At the heart of the controversy lies the 340B Drug Discount Program, a federal initiative designed to provide discounted medications to safety-net hospitals serving low-income patients. A separate but related proposal seeks to reduce Medicare payments for drugs obtained through this program by over 33%. This measure follows findings that some patients ended up paying more for certain medications than the hospitals themselves paid, prompting CMS to reassess its reimbursement rates. While the 340B program is intended to support community hospitals, the administration's stance suggests a preference for market-driven pricing models, raising concerns about the long-term viability of such programs.

The potential impact of these proposals extends beyond financial considerations. Nonprofit and academic hospitals, which rely heavily on the 340B program, have expressed strong opposition, warning that the changes could force them to cut services or even close doors. For-profit hospitals, on the other hand, might benefit from the new payment structure, as the proposal includes a modest increase in reimbursement for them. This disparity highlights the complex interplay between public and private sector interests within the U.S. healthcare landscape.

Reactions from stakeholders have been mixed. Advocacy groups representing safety-net hospitals have called the proposals "disproportionately harmful" and warned of a potential crisis for underserved communities. Meanwhile, industry representatives have praised the reforms as a necessary correction to outdated payment models. The debate has intensified amid ongoing discussions about the role of government in regulating healthcare costs and ensuring equitable access to care.

Looking ahead, the future of these policies remains uncertain. The proposed rules will likely face legal challenges and require approval from regulatory bodies before implementation. Additionally, the political climate surrounding healthcare reform continues to evolve, with potential legislative action or executive orders shaping the trajectory of these initiatives. As the administration moves forward, the balance between fiscal responsibility and patient care will remain central to the discourse, influencing both policy decisions and the broader healthcare ecosystem.

Go to the primary sources (1)

The official sources this coverage is built on. Read them directly to bypass framing.

2 reports

The Hill logoThe HillIndependentCenteryesterday
Trump administration wants to cut hospital payments for imaging

The Trump administration has proposed a rule from the Centers for Medicare and Medicaid Services (CMS) that would reduce hospital payments for certain imaging services. The change aims to equalize payments between hospitals and outpatient facilities, potentially leading to lower costs for seniors who receive routine imaging procedures. While the proposal could result in reduced expenses for patients, it raises concerns about the financial impact on hospitals and the quality of care. The move reflects broader efforts to reform healthcare spending and shift some services away from inpatient settings.

Bias read (Center): The article presents the proposal as a policy initiative without overtly criticizing or praising the administration's stance. It focuses on the potential effects of the policy rather than taking a clear ideological position. The framing remains neutral, emphasizing the administrative action and its'

STAT News logoSTAT NewsIndependentCenteryesterday
STAT+: Medicare takes another swing at 340B cuts to hospitals

Medicare has proposed reducing payments to hospitals for drugs purchased through the 340B drug discount program by over a third starting next year. This comes after Medicare's surveys indicated that some patients were paying more for these drugs than the hospitals did. Under the new proposal, Medicare would reimburse hospitals at the average sales price of the drugs minus 33.4%, significantly lower than the current rate of that price plus 6%. The proposal is part of a broader rule on hospital outpatient payments and has sparked controversy, with nonprofit and academic hospitals criticizing it for potentially harming safety-net providers. These hospitals are the only ones eligible for the 340B program, while for-profit hospitals would see a 7.4% pay increase under the same adjustment.

Bias read (Center): The article presents the Medicare proposal and includes reactions from both supporters and critics of the 340B program. It does not exhibit clear bias toward either side, providing information on the potential impacts on different types of hospitals without overtly favoring one perspective over the.

Keep the news honest.

ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €5/month.

Become a Supporter

Related stories